Drug Profile
IDX 9059
Alternative Names: DIMS-9059; IDX 9059Latest Information Update: 25 Nov 2022
Price :
$50
*
At a glance
- Originator InDex Pharmaceuticals
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 25 Nov 2022 IDX 9050 is still in preclinical development for Inflammation in Sweden (Index Pharmaceuticals pipeline, November 2022)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)
- 28 Apr 2020 Preclinical development is still ongoing for inflammation in Sweden (Index pharmaceuticals pipelines, April 2020)